Aptamers in cancer therapy: Why has clinical translation lagged behind preclinical promise?
Thoa T Tran, Vu L. Tran, Melissa L. Fishel, Ba-Thong Nguyen et autres
Aptamers have attracted substantial interest as cancer therapeutics due to their high target specificity, chemical programmability, and versatility in drug and RNA delivery; however, despite extensive preclinical development, clinical translation in oncology has remained extremely limited, with no aptamer-based therapies approved for …
us (code pays fourni par la source)